James Michael Milburn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James Michael Milburn has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Joshua A. Hirsch
Neuroendovascular Program, Massachusetts General Hospital, Boston, Massachusetts, USA
15 shared publications - Reade De Leacy
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
7 shared publications - Maitray D. Patel
Department of Radiology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054
6 shared publications Ann K. Jay
Department of Radiology, Medstar Georgetown University Hospital, Washington, DC
5 shared publicationsCarolynn M. DeBenedectis
Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts
5 shared publicationsChristopher P. Ho
Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia
5 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (10) , 1961-1963
The productivity benchmark trap: how lagging survey data and selective blending compound CMS reimbursement cuts for employed neurointerventionalists
These instruments provide employers with a nationally referenced framework for setting wRVU productivity targets and calibrating compensation-per-wRVU rates. When administered and applied in a methodologically sound manner they serve a legitimate function in establishing fair market value and ensuring compliance with Stark Laws and the Anti-Kickback Statute.6 The wRVU is no longer a ‘stable currency’ due to a multiyear pattern of structural upward drift in survey benchmarks, a 2026 Centers for Medicare and Medicaid Services (CMS) policy shift that amplifies that drift, and employer blending practices that amplify the resulting distortions. For employed neurointerventionalists, the net effect is a compounding, structurally embedded disadvantage that accumulates with each successive fee schedule cycle.
- 14 September 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (10) , 1961-1963
Open AccessThe productivity benchmark trap: how lagging survey data and selective blending compound CMS reimbursement cuts for employed neurointerventionalists
These instruments provide employers with a nationally referenced framework for setting wRVU productivity targets and calibrating compensation-per-wRVU rates. When administered and applied in a methodologically sound manner they serve a legitimate function in establishing fair market value and ensuring compliance with Stark Laws and the Anti-Kickback Statute.6 The wRVU is no longer a ‘stable currency’ due to a multiyear pattern of structural upward drift in survey benchmarks, a 2026 Centers for Medicare and Medicaid Services (CMS) policy shift that amplifies that drift, and employer blending practices that amplify the resulting distortions. For employed neurointerventionalists, the net effect is a compounding, structurally embedded disadvantage that accumulates with each successive fee schedule cycle.
- Open Access
- 5 May 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Impact of intravenous thrombolysis on aspiration thrombectomy outcomes: an Imperative Trial subgroup analysis
Background The impact of intravenous (IV) thrombolysis on the outcomes of aspiration thrombectomy as the primary endovascular approach to stroke in patients with large vessel occlusion is unknown. Methods The Imperative Trial was a prospective, investigational device exemption, multicenter trial of first-line aspiration thrombectomy that assessed the safety and efficacy of the Zoom System, including a novel 0.088 inch aspiration catheter in patients with stroke within 8 hours of onset. We compared procedural, technical, and clinical outcomes of aspiration thrombectomy based on whether patients had received IV thrombolytics prior to the intervention. Results Among the 260 patients treated with front-line aspiration thrombectomy using the Zoom System, 125 (48%) received IV thrombolysis prior to aspiration. Rates of modified Thrombolysis in Cerebral Infarction (mTICI) ≥2b achieved with the Zoom System were higher in the aspiration-only group than in the combined group (92% vs 81%, P=0.016). Rates of mTICI ≥2c and first pass effect were similar. The use of rescue devices to achieve mTICI ≥2b was less frequent in the aspiration-only group than in the combined group (2% vs 10%, P=0.008). The rates of functional independence (modified Rankin Scale (mRS) score 0–2) in the aspiration-only group and the combined group were 50% and 59%, respectively (P=0.16). Univariate (P=0.30) and multivariate (P=0.47) ordinal regression analyses showed no significant correlation of mRS 0–2 with IV thrombolysis. Both groups had similar safety outcomes including rates of symptomatic intracranial hemorrhage and 90-day mortality. Conclusions Aspiration thrombectomy alone may result in higher rates of successful reperfusion and reduce the need for rescue devices compared with the combined approach with IV thrombolysis.
- 5 May 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Open AccessImpact of intravenous thrombolysis on aspiration thrombectomy outcomes: an Imperative Trial subgroup analysis
Background The impact of intravenous (IV) thrombolysis on the outcomes of aspiration thrombectomy as the primary endovascular approach to stroke in patients with large vessel occlusion is unknown. Methods The Imperative Trial was a prospective, investigational device exemption, multicenter trial of first-line aspiration thrombectomy that assessed the safety and efficacy of the Zoom System, including a novel 0.088 inch aspiration catheter in patients with stroke within 8 hours of onset. We compared procedural, technical, and clinical outcomes of aspiration thrombectomy based on whether patients had received IV thrombolytics prior to the intervention. Results Among the 260 patients treated with front-line aspiration thrombectomy using the Zoom System, 125 (48%) received IV thrombolysis prior to aspiration. Rates of modified Thrombolysis in Cerebral Infarction (mTICI) ≥2b achieved with the Zoom System were higher in the aspiration-only group than in the combined group (92% vs 81%, P=0.016). Rates of mTICI ≥2c and first pass effect were similar. The use of rescue devices to achieve mTICI ≥2b was less frequent in the aspiration-only group than in the combined group (2% vs 10%, P=0.008). The rates of functional independence (modified Rankin Scale (mRS) score 0–2) in the aspiration-only group and the combined group were 50% and 59%, respectively (P=0.16). Univariate (P=0.30) and multivariate (P=0.47) ordinal regression analyses showed no significant correlation of mRS 0–2 with IV thrombolysis. Both groups had similar safety outcomes including rates of symptomatic intracranial hemorrhage and 90-day mortality. Conclusions Aspiration thrombectomy alone may result in higher rates of successful reperfusion and reduce the need for rescue devices compared with the combined approach with IV thrombolysis.
- 13 January 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1194-1195
Navigating the CY 2026 physician fee schedule: lessons from neurointerventional advocacy on CPT 61624 and 61626
- 13 January 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1194-1195
Navigating the CY 2026 physician fee schedule: lessons from neurointerventional advocacy on CPT 61624 and 61626
- 17 November 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (5) , 849-855
Promises and Challenges of Medicare Advantage
- 17 November 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (5) , 849-855
Promises and Challenges of Medicare Advantage
- Open Access
- 10 November 2025
- Published by Wiley in Epilepsia Open
- Vol. 11 (1) , 29-52
Diagnostic performance of neuroimaging modalities for epileptogenic focus localization: A systematic review
Objective: Accurate localization of epileptogenic foci remains of significant importance for surgical planning in drug‐resistant epilepsy. Multiple neuroimaging modalities are available; however, their comparative diagnostic performance lacks comparative detailed synthesis. This systematic review aimed to evaluate and compare the diagnostic accuracy of structural MRI, PET imaging, SPECT/SISCOM, and combined multimodal strategies for epileptogenic focus localization. Methods: We conducted a systematic review following PRISMA 2020 guidelines, searching PubMed, Scopus, Google Scholar, Cochrane Library, and Web of Science databases up to May 30, 2025. Studies evaluating the diagnostic performance of neuroimaging modalities for epilepsy focus localization with surgical correlation were included. Data extraction focused on sensitivity, specificity, and clinical manner. Quality assessment used QUADAS‐2 criteria. Results: Fifteen studies included a total of 1157 patients that met inclusion criteria. Combined multimodal strategies integrating two or more imaging modalities demonstrated the highest diagnostic performance (sensitivity 82–100%), followed by structural MRI in lesional epilepsy (72–100% sensitivity). PET imaging showed consistent performance across clinical contexts (33–89% sensitivity), while SPECT/SISCOM exhibited variable results (33–83% sensitivity). Strong complementarity existed between MRI and PET (85% concordance), with context‐dependent optimization for lesional versus non‐lesional epilepsy. Significance: Combined multimodal neuroimaging provides superior diagnostic performance for epileptogenic focus localization. Clinical context significantly impacts the modality selection, with MRI prioritized in lesional cases and functional imaging essential for MRI‐negative epilepsy. These findings support evidence‐based imaging protocols for surgical epilepsy evaluation. Plain Language Summary: This systematic review evaluated which brain imaging techniques are best for finding the exact location where seizures start in people with drug‐resistant epilepsy who need surgery. The researchers analyzed 15 studies involving 1157 patients. They found that using multiple imaging techniques together (combining structural and functional imaging) provides the most accurate results, with success rates of 82–100%. Standard MRI scans work very well (72–100% accuracy) when there is a visible brain abnormality causing seizures. However, for patients whose MRI looks normal, additional functional imaging techniques like PET or SPECT scans are crucial, achieving 63–89% accuracy. The study shows that the best imaging approach depends on the individual patient's situation: MRI should be used first when a brain lesion is suspected, but functional imaging becomes essential when MRI does not show anything abnormal. These findings help doctors choose the right combination of imaging tests for each patient to improve surgical planning and outcomes.
- 10 November 2025
- Published by Wiley in Epilepsia Open
- Vol. 11 (1) , 29-52
Open AccessDiagnostic performance of neuroimaging modalities for epileptogenic focus localization: A systematic review
Objective: Accurate localization of epileptogenic foci remains of significant importance for surgical planning in drug‐resistant epilepsy. Multiple neuroimaging modalities are available; however, their comparative diagnostic performance lacks comparative detailed synthesis. This systematic review aimed to evaluate and compare the diagnostic accuracy of structural MRI, PET imaging, SPECT/SISCOM, and combined multimodal strategies for epileptogenic focus localization. Methods: We conducted a systematic review following PRISMA 2020 guidelines, searching PubMed, Scopus, Google Scholar, Cochrane Library, and Web of Science databases up to May 30, 2025. Studies evaluating the diagnostic performance of neuroimaging modalities for epilepsy focus localization with surgical correlation were included. Data extraction focused on sensitivity, specificity, and clinical manner. Quality assessment used QUADAS‐2 criteria. Results: Fifteen studies included a total of 1157 patients that met inclusion criteria. Combined multimodal strategies integrating two or more imaging modalities demonstrated the highest diagnostic performance (sensitivity 82–100%), followed by structural MRI in lesional epilepsy (72–100% sensitivity). PET imaging showed consistent performance across clinical contexts (33–89% sensitivity), while SPECT/SISCOM exhibited variable results (33–83% sensitivity). Strong complementarity existed between MRI and PET (85% concordance), with context‐dependent optimization for lesional versus non‐lesional epilepsy. Significance: Combined multimodal neuroimaging provides superior diagnostic performance for epileptogenic focus localization. Clinical context significantly impacts the modality selection, with MRI prioritized in lesional cases and functional imaging essential for MRI‐negative epilepsy. These findings support evidence‐based imaging protocols for surgical epilepsy evaluation. Plain Language Summary: This systematic review evaluated which brain imaging techniques are best for finding the exact location where seizures start in people with drug‐resistant epilepsy who need surgery. The researchers analyzed 15 studies involving 1157 patients. They found that using multiple imaging techniques together (combining structural and functional imaging) provides the most accurate results, with success rates of 82–100%. Standard MRI scans work very well (72–100% accuracy) when there is a visible brain abnormality causing seizures. However, for patients whose MRI looks normal, additional functional imaging techniques like PET or SPECT scans are crucial, achieving 63–89% accuracy. The study shows that the best imaging approach depends on the individual patient's situation: MRI should be used first when a brain lesion is suspected, but functional imaging becomes essential when MRI does not show anything abnormal. These findings help doctors choose the right combination of imaging tests for each patient to improve surgical planning and outcomes.
- Open Access
- 23 October 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (10) , 1990-1996
Unseen wounds: a multinational investigation of neurointerventionalists on the psychological toll of complications
Background Complications not only affect patients but also impose a significant psychological burden on physicians. Quantitative data in neurointerventional surgery regarding the ‘second victim’ phenomenon are lacking. This study aimed to assess the prevalence and severity of post-traumatic stress symptoms among neurointerventionalists after major complications. Methods A survey was developed by a committee of experienced neurointerventionalists and distributed internationally via multiple platforms. Respondents were anonymous. Demographic information, complication type, and institutional support availability were queried. Psychological distress was measured using the validated Impact of Event Scale-Revised (IES-R), which assesses intrusion, avoidance, and hyperarousal domains. Descriptive statistics and regression analyses were performed to identify factors associated with post-traumatic stress symptoms. Results Of 1042 invited physicians, 503 responded (48%), with 413 completing the full survey (40%). The most common pathology was cerebral aneurysm, and the most frequent complication was hemorrhage. Overall, 64% scored above the IES-R threshold for possible post-traumatic stress disorder (PTSD) (≥24), with many reaching levels (≥37) associated with long-term stress and physiological sequelae. Intrusion was the dominant symptom domain, particularly distressing reminders about the complication. Lack of institutional support was significantly associated with possible PTSD (OR 1.63, 95% CI 1.1 to 2.5, P=0.02). No differences were observed by specialty, but geographic variations were present. High stress scores persisted long after the index event. Conclusion Complications exert a profound emotional and physiological toll on neurointerventionalists, with high rates of possible PTSD and a strong association with inadequate institutional support. Systematic support programs are urgently needed to safeguard physician well-being and patient safety.
- 23 October 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (10) , 1990-1996
Open AccessUnseen wounds: a multinational investigation of neurointerventionalists on the psychological toll of complications
Background Complications not only affect patients but also impose a significant psychological burden on physicians. Quantitative data in neurointerventional surgery regarding the ‘second victim’ phenomenon are lacking. This study aimed to assess the prevalence and severity of post-traumatic stress symptoms among neurointerventionalists after major complications. Methods A survey was developed by a committee of experienced neurointerventionalists and distributed internationally via multiple platforms. Respondents were anonymous. Demographic information, complication type, and institutional support availability were queried. Psychological distress was measured using the validated Impact of Event Scale-Revised (IES-R), which assesses intrusion, avoidance, and hyperarousal domains. Descriptive statistics and regression analyses were performed to identify factors associated with post-traumatic stress symptoms. Results Of 1042 invited physicians, 503 responded (48%), with 413 completing the full survey (40%). The most common pathology was cerebral aneurysm, and the most frequent complication was hemorrhage. Overall, 64% scored above the IES-R threshold for possible post-traumatic stress disorder (PTSD) (≥24), with many reaching levels (≥37) associated with long-term stress and physiological sequelae. Intrusion was the dominant symptom domain, particularly distressing reminders about the complication. Lack of institutional support was significantly associated with possible PTSD (OR 1.63, 95% CI 1.1 to 2.5, P=0.02). No differences were observed by specialty, but geographic variations were present. High stress scores persisted long after the index event. Conclusion Complications exert a profound emotional and physiological toll on neurointerventionalists, with high rates of possible PTSD and a strong association with inadequate institutional support. Systematic support programs are urgently needed to safeguard physician well-being and patient safety.
- Open Access
- 12 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1027-1028
Medicare Advantage plans: who gets the advantage?
- 12 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1027-1028
Open AccessMedicare Advantage plans: who gets the advantage?
- Open Access
- 4 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1857-1863
Clinical outcomes and independently adjudicated results of M2 aspiration thrombectomy: a subgroup analysis from the Imperative Trial
Background The ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions) and DISTAL (Endovascular Therapy plus Best Medical Treatment vs Best Medical Treatment Alone for Medium Vessel Occlusion Stroke) trials failed to demonstrate the superiority of endovascular thrombectomy over best medical management for medium and small vessel occlusions. Potential limitations of these trials include older patient populations, lower presenting National Institutes of Health Stroke Scale (NIHSS) scores, higher rates of premorbid disability, delayed revascularization times, inclusion of both medium and small vessel occlusions, and widespread use of stent retrievers. Here we present M2 occlusion data from the Imperative Trial, evaluating aspiration thrombectomy with the Zoom System. Methods The Imperative Trial is a prospective, multicenter, single-arm trial with independent core lab and safety board adjudication, evaluating aspiration thrombectomy with the Zoom System (Imperative Care, Campbell, CA, USA) for large vessel, including M2, occlusions. This subanalysis includes patients with primary M2 occlusions. Angiographic outcomes were defined as modified Treatment in Cerebral Infarction (mTICI) score ≥2b (good) and ≥2c (excellent). Clinical outcomes were defined as modified Rankin Scale score (mRS) 0–2 (good) and 0–1 (excellent) at 90 days. Safety was assessed by all-cause mortality, symptomatic intracranial hemorrhage (sICH), and all hemorrhage. Results Of 260 enrolled patients, 25% (65/260) had primary M2 occlusions. Median age was 69 years; median NIHSS was 13. Good and excellent reperfusion were achieved in 88% (57/65) and 66% (43/65), respectively. At 90 days, good and excellent clinical outcomes occurred in 62% (39/63) and 56% (35/63), respectively. Mortality, sICH, and any hemorrhage were 4.6% (3/65), 1.5% (1/65), and 18% (12/65), respectively. Conclusions The Zoom System demonstrated excellent safety and efficacy in M2 occlusions. These findings support aspiration thrombectomy for M2 occlusions as a viable treatment in well-selected patients.
- 4 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1857-1863
Open AccessClinical outcomes and independently adjudicated results of M2 aspiration thrombectomy: a subgroup analysis from the Imperative Trial
Background The ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions) and DISTAL (Endovascular Therapy plus Best Medical Treatment vs Best Medical Treatment Alone for Medium Vessel Occlusion Stroke) trials failed to demonstrate the superiority of endovascular thrombectomy over best medical management for medium and small vessel occlusions. Potential limitations of these trials include older patient populations, lower presenting National Institutes of Health Stroke Scale (NIHSS) scores, higher rates of premorbid disability, delayed revascularization times, inclusion of both medium and small vessel occlusions, and widespread use of stent retrievers. Here we present M2 occlusion data from the Imperative Trial, evaluating aspiration thrombectomy with the Zoom System. Methods The Imperative Trial is a prospective, multicenter, single-arm trial with independent core lab and safety board adjudication, evaluating aspiration thrombectomy with the Zoom System (Imperative Care, Campbell, CA, USA) for large vessel, including M2, occlusions. This subanalysis includes patients with primary M2 occlusions. Angiographic outcomes were defined as modified Treatment in Cerebral Infarction (mTICI) score ≥2b (good) and ≥2c (excellent). Clinical outcomes were defined as modified Rankin Scale score (mRS) 0–2 (good) and 0–1 (excellent) at 90 days. Safety was assessed by all-cause mortality, symptomatic intracranial hemorrhage (sICH), and all hemorrhage. Results Of 260 enrolled patients, 25% (65/260) had primary M2 occlusions. Median age was 69 years; median NIHSS was 13. Good and excellent reperfusion were achieved in 88% (57/65) and 66% (43/65), respectively. At 90 days, good and excellent clinical outcomes occurred in 62% (39/63) and 56% (35/63), respectively. Mortality, sICH, and any hemorrhage were 4.6% (3/65), 1.5% (1/65), and 18% (12/65), respectively. Conclusions The Zoom System demonstrated excellent safety and efficacy in M2 occlusions. These findings support aspiration thrombectomy for M2 occlusions as a viable treatment in well-selected patients.
- Open Access
- 22 July 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1202-1209
Stroke thrombectomy with a novel reperfusion system including a 0.088′′ aspiration catheter: the Imperative Trial
Background Mechanical thrombectomy is the standard of care for large vessel occlusion (LVO) stroke, yet most device trials focus on individual technologies rather than complete systems. Objective To evaluate the safety and efficacy of the Zoom Reperfusion System compared with performance goals derived from a meta-analysis of trials using established thrombectomy technologies. Methods Prospective, multicenter, non-randomized, investigational device exemption trial conducted across 26 United States centers from October 2021 to March 2024. Adults with anterior circulation LVO stroke within 8 hours of onset were treated using the Zoom System, which includes aspiration catheters ranging from 0.035″ to 0.071″, and a novel 0.088″ intracranial guide/aspiration catheter. The primary efficacy endpoint was successful reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3) within three passes using Zoom-only components, adjudicated by an independent core laboratory. The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included final reperfusion, first-pass success, time to reperfusion, 90-day modified Rankin Scale (mRS), and mortality. Results Among 260 patients (median age 68 years; median National Institutes of Health Stroke Scale (NIHSS) 15), successful reperfusion within three passes was achieved in 83% (216/259; 95% CI: 78% to 89%), exceeding the performance goal (pConclusions The Zoom Reperfusion System demonstrated a safety and efficacy profile exceeding prespecified contemporary performance metrics with potential to significantly shorten reperfusion times and reduce the need for rescue therapy. Trial registration number ClinicalTrials.gov--Identifier:NCT04129125.
- 22 July 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1202-1209
Open AccessStroke thrombectomy with a novel reperfusion system including a 0.088′′ aspiration catheter: the Imperative Trial
Background Mechanical thrombectomy is the standard of care for large vessel occlusion (LVO) stroke, yet most device trials focus on individual technologies rather than complete systems. Objective To evaluate the safety and efficacy of the Zoom Reperfusion System compared with performance goals derived from a meta-analysis of trials using established thrombectomy technologies. Methods Prospective, multicenter, non-randomized, investigational device exemption trial conducted across 26 United States centers from October 2021 to March 2024. Adults with anterior circulation LVO stroke within 8 hours of onset were treated using the Zoom System, which includes aspiration catheters ranging from 0.035″ to 0.071″, and a novel 0.088″ intracranial guide/aspiration catheter. The primary efficacy endpoint was successful reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3) within three passes using Zoom-only components, adjudicated by an independent core laboratory. The primary safety endpoint was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included final reperfusion, first-pass success, time to reperfusion, 90-day modified Rankin Scale (mRS), and mortality. Results Among 260 patients (median age 68 years; median National Institutes of Health Stroke Scale (NIHSS) 15), successful reperfusion within three passes was achieved in 83% (216/259; 95% CI: 78% to 89%), exceeding the performance goal (pConclusions The Zoom Reperfusion System demonstrated a safety and efficacy profile exceeding prespecified contemporary performance metrics with potential to significantly shorten reperfusion times and reduce the need for rescue therapy. Trial registration number ClinicalTrials.gov--Identifier:NCT04129125.
- 29 April 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (8) , 790-791
Commentary on the River Stent Trial: Venous Sinus Stenting is Safe and Effective and can be Fully Evaluated Using Noninvasive Methods
- 29 April 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (8) , 790-791
Commentary on the River Stent Trial: Venous Sinus Stenting is Safe and Effective and can be Fully Evaluated Using Noninvasive Methods